|
| Development Program |
Indication |
Development Stage |
|
| Chenorm® (chenodeoxycholic acid) Capsules |
Treatment of cerebrotendious xanthomatosis (CTX) |
NDA/Registration |
| CystoranTM (cysteamine hydrochloride) Ophthalmic Solution 0.55% |
Treatment of ocular crystals for patients with cystinosis |
NDA Preparation |
| Defibrotide in severe Venous Occlusive Disease |
Hepatic venous occlusive disease after stem cell transplantation |
Phase III |
| Nuartez® (artesunate) Injection in severe malaria |
Immediate treatment of severe and complicated falciparum malaria |
NDA/Registration |
| STP-368 live biotherapeutic |
Prevention of necrotizing enterocolitis (NEC) |
Preclinical/Phase I |
|
